

Pubblicazioni Programma Prostata

2015

Cozzarini C, Rancati T, Carillo V, Civardi F, Garibaldi E, Franco P, Avuzzi B, Esposti CD, Girelli G, Iotti C, Palorini F, Vavassori V, Valdagni R, Fiorino C. Multi-variable models predicting specific patient-reported acute urinary symptoms after radiotherapy for prostate cancer: Results of a cohort study. *Radiother Oncol*. 2015 Aug 11. pii: S0167-8140(15)00409-0. [Epub ahead of print]

Bokhorst LP, Alberts AR, Rannikko A, Valdagni R, Pickles T, Kakehi Y, Bangma CH, Roobol MJ; PRIAS study group. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers. *Eur Urol* pii: S0302-2838(15)00515-1, 2015[Epub ahead of print]

Valdagni R, Van Poppel H, Aitchison M, Albers P, Berthold D, Bossi A, Brausi M, Denis L, Drudge-Coates L, De Santis M, Feick G, Harrison C, Haustermans K, Hollywood D, Hoyer M, Hummel H, Mason M, Mirone V, Müller SC, Parker C, Saghatchian M, Sternberg CN, Tombal B, van Muilekom E, Watson M, Wesselmann S, Wiegel T, Magnani T, Costa A. Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. *Crit Rev Oncol Hematol* 95(2):133-43, 2015

Vasarainen H, Salman J, Salminen H, Valdagni R, Pickles T, Bangma C, Roobol MJ, Rannikko A. Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS). *World J Urol*. 2015 Mar 31. [Epub ahead of print]

Jereczek-Fossa BA, Colombo R, Magnani T, Fodor C, Gerardi MA, Antognoni P, Barsacchi L, Bedini N, Bracelli S, Buffoli A, Cagna E, Catalano G, Gottardo S, Italia C, Ivaldi GB, Masciullo S, Merlotti A, Sarti E, Scorsetti M, Serafini F, Toninelli M, Vitali E, Valdagni R, Villa E, Zerini D, De Cobelli O, Orecchia R. Urinary bladder preservation for muscle-invasive bladder cancer: a survey among radiation oncologists of Lombardy, Italy. *Tumori* 101(2):174-8, 2015

Bangma CH, Valdagni R, Carroll PR, van Poppel H, Klotz L, Hugosson J. Active Surveillance for Low-risk Prostate Cancer: Developments to Date. *Eur Urol* 67(4):646-8, 2015

Bellardita L, Valdagni R, van den Bergh R, Randsdorp H, Repetto C, Venderbos L D F, Lane J A, Korfage I J, How Does Active Surveillance for Prostate Cancer Affect Quality of Life? A Systematic Review. *Eur Urol* 67 (4):637-645, 2015

Cavalieri F, Beretta GL, Cui J, Braunger JA, Yan Y, Richardson JJ, Tinelli S, Folini M, Zaffaroni N, Caruso F. Redox-Sensitive PEG-Polypeptide Nanoporous Particles for Survivin Silencing in Prostate Cancer Cells. *Biomacromolecules* 16(7):2168-78, 2015.

Beretta GL, Folini M, Cavalieri F, Yan Y, Fresch E, Kaliappan S, Hasenöhr C, Richardson JJ, Tinelli S, Fery A, Caruso F, Zaffaroni N. Unravelling "off-target" effects of redox-active polymers and polymer multilayered capsules in prostate cancer cells. *Nanoscale* 7(14):6261-70, 2015.

Pennati M, Folini M, Gandellini P, Zaffaroni N. MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs. *Curr Drug Targets*. 2015 Mar 16. [Epub ahead of print]

Gravina GL, Tortoreto M, Mancini A, Addis A, Di Cesare E, Lenzi A, Landesman Y, McCauley D, Kauffman M, Shacham S, Zaffaroni N, Festuccia C. XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). *J Hematol Oncol* 5;7:46, 2015.

2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeny LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R, Verhaegh G, van Zelst-Stams WA, Oosterwijk JC, Blanco I, Salinas M, Cook J, Rosario DJ, Buys S, Conner T, Ausems MG, Ong KR, Hoffman J, Domchek S, Powers J, Teixeira MR, Maia S, Foulkes WD, Taherian N, Ruijs M, Helderma-van den Enden AT, Izatt L, Davidson R, Adank MA, Walker L, Schmutzler R, Tucker K, Kirk J, Hodgson S, Harris M, Douglas F, Lindeman GJ, Zgajnar J, Tischkowitz M, Clowes VE, Susman R, Ramón y Cajal T, Patcher N, Gadea N, Spigelman A, van Os T, Liljegren A, Side L, Brewer C, Brady AF, Donaldson A, Stefansdottir V, Friedman E, Chen-Shtoyerman R, Amor DJ, Copakova L, Barwell J, Giri VN, Murthy V, Nicolai N, Teo SH, Greenhalgh L, Strom S, Henderson A, McGrath J, Gallagher D, Aaronson N, Ardern-Jones A, Bangma C, Dearnaley D, Costello P, Eyfjord J, Rothwell J, Falconer A, Gronberg H, Hamdy FC, Johannsson O, Khoo V, Kote-Jarai Z, Lubinski J, Axcrona U, Melia J, McKinley J, Mitra AV, Moynihan C, Rennert G, Suri M, Wilson P, Killick E; IMPACT Collaborators (Valdagni R), Moss S, Eeles RA. Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. *Eur Urol* 66(3):489-499, 2014

Voigt W, Hoellthaler J, Magnani T, Corrao V, Valdagni R. 'Act on oncology' as a new comprehensive approach to assess prostate cancer centres - method description and results of a pilot study. *PLoS One* 9(9):e106743, 2014

West C, Azria D, Chang-Claude J, Davidson S, Lambin P, Rosenstein B, De Ruyscher D, Talbot C, Thierens H, Valdagni R, Vega A, Yuille M. The REQUITE Project: Validating Predictive Models and Biomarkers of Radiotherapy Toxicity to Reduce Side-effects and Improve Quality of Life in Cancer Survivors. *Clin Oncol (R Coll Radiol)* pii: S0936-6555(14)00341-0, 2014

Gandellini P, Rancati T, Valdagni R, Zaffaroni N. miRNAs in tumor radiation response: bystanders or participants? *Trends Mol Med* 20(9):529-539, 2014

Maggio A, Magli A, Rancati T, Fiorino C, Valvo F, Fellin G, Ricardi U, Munoz F, Cosentino D, Cazzaniga LF, Valdagni R, Vavassori V. Daily sodium butyrate enema for the prevention of radiation proctitis in prostate cancer patients undergoing radical radiation therapy: results of a multicenter randomized placebo-controlled dose-finding phase 2 study. *Int J Radiat Oncol Biol Phys* 89(3):518-24, 2014

Bellardita L, Villa S, Valdagni R. Living with untreated prostate cancer: predictors of quality of life. *Curr Opin Urol* 24(3):311-7, 2014

Carillo V, Cozzarini C, Rancati T, Avuzzi B, Botti A, Borca VC, Cattari G, Civardi F, Esposti CD, Franco P, Girelli G, Maggio A, Muraglia A, Palombarini M, Pierelli A, Pignoli E, Vavassori V, Zeverino M, Valdagni R, Fiorino C. Relationships between bladder dose-volume/surface histograms and acute urinary toxicity after radiotherapy for prostate cancer. *Radiother Oncol* 111(1):100-5, 2014

Killick E, Tymrakiewicz M, Cieza-Borrella C, Smith P, Thompson DJ, Pooley KA, Easton DF, Bancroft E, Page E, Leongamornlert D; IMPACT collaborators (Valdagni R), Kote-Jarai Z, Eeles RA. Telomere length shows no association with BRCA1 and BRCA2 mutation status. *PLoS One* 9(1):e86659, 2014. eCollection 2014

Pennati M, Lopergolo A, Profumo V, De Cesare M, Sbarra S, Valdagni R, Zaffaroni N, Gandellini P, Folini M. miR-205 impairs the autophagic flux and enhances cisplatin cytotoxicity in castration-resistant prostate cancer cells. *Biochem Pharmacol* 87(4):579-97, 2014

Fellin G, Rancati T, Fiorino C, Vavassori V, Antognoni P, Baccolini M, Bianchi C, Cagna E, Borca VC, Girelli G, Iacopino B, Maliverni G, Mauro FA, Menegotti L, Monti AF, Romani F, Stasi M, Valdagni R. Long term rectal function after high-dose prostate cancer radiotherapy: Results from a prospective cohort study. *Radiother Oncol* 110(2):272-7, 2014

Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Piovan C, Valdagni R, Pierotti MA, Zaffaroni N, Chiarugi P. miR-205 Hinders the Malignant Interplay Between Prostate Cancer Cells and Associated Fibroblasts. *Antioxid Redox Signal* 20(7): 1045-59, 2014

Tombal B, Alcaraz A, James N, Valdagni R, Irani J. Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? *BJU Int* 113/2:189-99, 2014

Taddei ML, Cavallini L, Comito G, Giannoni E, Folini M, Marini A, Gandellini P, Morandi A, Pintus G, Raspollini MR, Zaffaroni N, Chiarugi P. Senescent stroma promotes prostate cancer progression: the role of miR-210. *Mol Oncol* 8(8):1729-46, 2014

Fiorino C, Cozzarini C, Rancati T, Briganti A, Cattaneo GM, Mangili P, Di Muzio NG, Calandrino R. Modelling the impact of fractionation on late urinary toxicity after postprostatectomy radiation therapy. *Int J Radiat Oncol Biol Phys* 90(5):1250-7, 2014

2013

Bellardita L, Rancati T, Valdagni R. Editorial Comment to Health-related quality of life after carbon-ion radiotherapy for prostate cancer: A 3-year prospective study. *Int J Urol* 2013 Nov 2013

Horwich A1, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V; Panel Members (Valdagni R); European Society for Medical Oncology. Prostate cancer: ESMO Consensus Conference Guidelines 2012. *Ann Oncol* 24(5):1141-62, 2013

Valdagni R, Rancati T. Reducing rectal injury during external beam radiotherapy for prostate cancer. *Nat Rev Urol* 10(6):345-57, 2013

Descovich M, Carrara M, Morlino S, Pinnaduwege DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. *J Appl Clin Med Phys* 14(5):4333, 2013

Procopio G, Grassi P, Testa I, Verzoni E, Torri V, Salvioni R, Valdagni R, de Braud F. Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. *Am J Clin Oncol*. 2013 Sep 21. [Epub ahead of print]

Bellardita L, Valdagni R, Rancati T. Reply from Authors re: Laurence Klotz. Active Surveillance, Quality of Life, and Cancer-related Anxiety. *Eur Urol*. 2013; 64:37-9: Active Surveillance: Risk and Protective Factors for Quality of Life. *Eur Urol* 64(1):39-40, 2013

Maggio A, Carillo V, Cozzarini C, Perna L, Rancati T, Valdagni R, Gabriele P, Fiorino C. Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. *Phys Med Biol* 58(7):N115-23, 2013

Bellardita L, Rancati T, Alvisi MF, Villani D, Magnani T, Marengi C, Nicolai N, Procopio G, Villa S, Salvioni R, Valdagni R. Predictors of Health-related Quality of Life and Adjustment to Prostate Cancer During Active Surveillance. *Eur Urol* 64(1): 30-6, 2013

Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ. Active Surveillance for Low-Risk Prostate Cancer Worldwide: The PRIAS Study. *Eur Urol* 64(4):597-603, 2013

Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, Steyerberg EW, Jenster G, Kattan MW, Bellardita L, Carroll PR, Denis LJ, Parker C, Roobol MJ, Emberton M, Klotz LH, Rannikko A, Kakehi Y, Lane JA, Schröder FH, Semjonow A, Trock BJ, Valdagni R. Active surveillance for low-risk prostate cancer. *Crit Rev Oncol Hematol* 85(3):295-302, 2013

2012

Rivoltini L, Marrari A, Castelli C, Villa S, Valdagni R. Don't run before you can walk. *Nat Rev Urol* 9(10):602, 2012

Carillo V, Cozzarini C, Chietera A, Perna L, Gianolini S, Maggio A, Botti A, Rancati T, Valdagni R, Fiorino C. Correlation between surrogates of bladder dosimetry and dose-volume histograms of the bladder wall defined on MRI in prostate cancer radiotherapy. *Radiother Oncol* 105(2):180-183, 2012

Gandellini P, Profumo V, Casamichele A, Fenderico N, Borrelli S, Petrovich G, Santilli G, Callari M, Colecchia M, Pozzi S, De Cesare M, Folini M, Valdagni R, Mantovani R, Zaffaroni N. miR-205 regulates basement membrane deposition in human prostate: implications for cancer development. *Cell Death Differ* 19(11):1750-60, 2012

Valdagni R, Vavassori V, Rancati T, Fellin G, Baccolini M, Bianchi C, Cagna E, Gabriele P, Mauro F, Menegotti L, Monti AF, Stasi M, Fiorino C. Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. *Radiother Oncol* 103 (2):252-255, 2012

Magnani T, Valdagni R, Salvioni R, Villa S, Bellardita L, Donegani S, Nicolai N, Procopio G, Bedini N, Rancati T, Zaffaroni N. The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. *BJU Int* 110(7):998-1003, 2012

Carillo V, Cozzarini C, Perna L, Calandra M, Gianolini S, Rancati T, Spinelli AE, Vavassori V, Villa S, Valdagni R, Fiorino C. Contouring Variability of the Penile Bulb on CT Images: Quantitative Assessment Using a Generalized Concordance Index. *Int J Radiat Oncol Biol Phys* 84(3):841-846, 2012

Tomatis S, Rancati T, Fiorino C, Vavassori V, Fellin G, Cagna E, Mauro FA, Girelli G, Monti A, Baccolini M, Naldi G, Bianchi C, Menegotti L, Pasquino M, Stasi M, Valdagni R. Late rectal bleeding after 3D-CRT for prostate cancer: development of a neural-network-based predictive model. *Phys Med Biol* 57(5):1399-412, 2012

Bellardita, L., Graffigna, G., Donegani, S., Villani, D., Villa, S., Tresoldi, V., Marengi, C., Magnani, T., Valdagni, R. Patient's choice of observational strategy for early-stage prostate cancer, *Neuropsychological Trends*, 12 (1), 107-116, 2012

Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ. Radical Prostatectomy for Low-Risk Prostate Cancer Following Initial Active Surveillance: Results From a Prospective Observational Study. *Eur Urol.* 62(2):195-200, 2012

Fiorino C, Rancati T, Fellin G, Vavassori V, Cagna E, Casanova Borca V, Girelli G, Menegotti L, Monti AF, Tortoreto F, Delle Canne S, Valdagni R. Late Fecal Incontinence After High-Dose Radiotherapy for Prostate Cancer: Better Prediction Using Longitudinal Definitions. *Int J Radiat Oncol Biol Phys* 83(1):38-45, 2012